Neuren Pharmaceuticals' Rett Syndrome Drug Secures Approval in Canada

MT Newswires Live

2024/10/17

Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.

Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.

The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.

Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.

Price (AUD): $12.99, Change: $+0.29, Percent Change: +2.28%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2476189923"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2476189923\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2476189923?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 08:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476189923","market":"sg","top_or_hot":-1,"title":"Neuren Pharmaceuticals' Rett Syndrome Drug Secures Approval in Canada","media":"MT Newswires Live","content":"<html><body><p> Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.</p><p>Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.</p><p>The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.</p><p>Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.</p><p>Price (AUD): $12.99, Change: $+0.29, Percent Change: +2.28%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals' Rett Syndrome Drug Secures Approval in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals' Rett Syndrome Drug Secures Approval in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-17 08:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.</p><p>Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.</p><p>The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.</p><p>Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.</p><p>Price (AUD): $12.99, Change: $+0.29, Percent Change: +2.28%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476189923","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476189923","pubTimestamp":1729126669,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals  said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.Price : $12.99, Change: $+0.29, Percent Change: +2.28%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK4125":"广播","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7508":"医药生物股"},"translate_title":"Neuren Pharmaceuticals的雷特综合症药物在加拿大获得批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9,"AUD":1},"content_text":"Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.Price (AUD): $12.99, Change: $+0.29, Percent Change: +2.28%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}